

Paris Brain Institute

OneBrain :
**Redefine boundaries of brain
diseases and accelerate
therapeutic breakthroughs
through large precision brain
health cohorts**

Marie MICOLON

Alliances Manager

marie.micolon@icm-institute.org



29 Research Teams



+900 Researchers




12 Core Facilities



65 Start-ups

5 Research Fields



A network of world-renowned experts



1. Pitié-Salpêtrière Hospital
2. Saint Antoine Hospital
3. Tenon Hospital
4. Rothschild Hospital
5. Charles Foix Hospital

Pitié Salpêtrière

The largest hospital in Europe

100 000

Patient's visit in CNS per year

3

National Clinical research network

14

National reference centers

Mission

A collaborative hub

to accelerate discoveries that will
improve the lives of patients with brain diseases
and **enhance brain health globally**

while leaving room for **curiosity-driven
fundamental discoveries** in neuroscience



Cross-sectional **strategic areas**



- ▶ Deciphering **brain function and disease**, across the **lifespan** and across **species**



- ▶ From computational neuroscience to **AI for neuroscience & neuroscience for AI**



- ▶ Towards **precision neuroscience** and **next-generation brain therapies**




- ▶ Reinforcing interdisciplinarity and developing **neuroscience with and for society**



- ▶ Enabling **curiosity-driven moonshot projects!**



Cutting-edge Technological Facilities and CRO



Clinical Capabilities dedicated to CNS

Clinical Platforms Human Imaging & Exploration

Dedicated to integrative, cognitive and clinical neuroscience

- **CENIR** : Center for Neuroimaging (3T and 7T MRI, PET, MEG-EEG)
- **Ultrasound**: high frequency ablation and low frequency BBB permeabilization
- **PRISME** : functional exploration of human behaviour and cognition
- **PANAM** : Physiology & Analysis of Movement
- **STIM** : stereotactic neurosurgery (DBS, etc.)

Clinical Investigation Center

- Promoting translational research
- Biomarker identification and assessment
- Genotyping and phenotyping approaches to characterize specific patient populations
- Longitudinal follow-up to 5 years (DNA extracts, cells, blood fluid)
- 57 Cohorts and databases (220,000 samples, 560 brains)
- 83 on-going trials
- 2000+ Patients' visits

Bioresources

Precision Neuroscience:

- >80,000 patients with neurological disease
- DNA (\pm RNA), plasma, serum, CSF, saliva, urine, PBMC, cells

Brain single-cell multiomics

- 1,207 human brains with fresh frozen tissue
- 19,972 brain tumors (18,270 patients)

Neuroimaging Resource

- >20,000 patients with 3T MRI
- + 2,000 patients (underway) with 7T + 2,000 population-based participants with 7T



Reference centers for rare neurological diseases

20 national reference centers for rare neurological diseases coordinated at Pitié-Salpêtrière Hospital with leading KOL in France :

- Huntington's disease
- Creutzfeldt-Jakob disease
- FTD
- Ataxias
- Dystonia
- ALS
- Spastic Paraplegia
- Congenital mirror movements
- Leukodystrophies
- Gilles de la Tourette Syndrome
- Progressive supranuclear palsy
- Essential tremors
- Primary brain tumors

14 led by PIs from Paris Brain Institute

▶ Associated biobanks (N = x10,000)

▶ Associated clinical records and imaging



Next-generation research databanks



► PRECISION NEUROSCIENCE BIORESOURCE

- **>80,000 patients** with neurological disease or presymptomatic high-risk individuals
- **DNA** (\pm RNA, plasma, serum, CSF, saliva, urine, PBMC, cells)

Pilot to generate (funding partly secured & under review)

- **GWAS** on 50,000 with regulatory clearance (1.5 M€)
- **LR-WGS (+ Methyl.)** on 3,000 deeply phenotyped* (2.5M€)
- **Simoa & OLINK HT proteomics** on 3,000 deeply phenotyped individuals* (2 M€) (* e.g. presymptomatic/dementia/ALS)


► BRAIN SINGLE-CELL MULTI-OMICS RESOURCE

- **1,207 human brains** with fresh frozen tissue
- **19,972 brain tumors** (18,270 patients)



Pilot to generate (funding partly secured & under review)

- **Single cell RNA seq** and **spatial transcriptomics (subset)** on 200 samples
- **Integration with** single-cell and spatial transcriptomics data in **model organisms**




► 7T POPULATION-BASED COHORT

- **+ 2,000 patients** (underway) **with 7T**
- **+ 2,000 population-based** participants **with 7T**

Pilot to generate (funding under review)

- **Population-based cohort of 2,000 participants on 7T MRI** linking with precision neuroscience bioresource (2 M€)
- **AI 3T -> Synthetic 7T**



AI & DATA SCIENCE STRATEGY

- Linking **Paris Brain Institute cohorts** to **clinical data warehouse** of AP-HP (incl. **imaging**)
- **Data sharing & Open science** strategy
- Streamline process for **secondary use**
- Reinforce **bioinformatics and AI resources**
- Optimize **IT infrastructure** for this use



Attractivity for public & private partners




Calls of interest for the **PBI**

- HORIZON-HLTH-2026-01-STAYHLTH-02 (single-stage): **Behavioural interventions** as primary prevention for Non-Communicable Diseases (NCDs) among **young people**
- HORIZON-HLTH-2026-01-ENVHLTH-01 (single stage): Towards a better understanding and anticipation of the **impacts of climate change on health**
- HORIZON-HLTH-2026-01-DISEASE-02 (single stage): Innovative interventions to prevent the **harmful effects** of using **digital technologies on the mental health of children and young adults**
- HORIZON-HLTH-2026-01-DISEASE-03 (single stage): Advancing research on the prevention, diagnosis, and management of **post-infection long-term conditions**
- HORIZON-HLTH-2026-02-DISEASE-12: European Partnership on **Rare Diseases** (ERDERA) (Phase 2)
- HORIZON-HLTH-2027-02-DISEASE-14-two-stage: **Clinical trials** for advancing innovative interventions for **neurodegenerative diseases**
- **OneBrain** HORIZON-HLTH-2027-02-TOOL-01-two-stage: **Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases**
- HORIZON-HLTH-2027-03-TOOL-04 (single stage): **Virtual Human Twins (VHTs)** for integrated clinical decision support in prevention and diagnosis
- HORIZON-HLTH-2027-03-TOOL-08 (single stage): Towards **Artificial General Intelligence (AGI)** for healthcare



Paris Brain Institute
OneBrain
Prospective real-life precision
neuroscience cohort



Challenges

- 1 in 3 people will experience a brain disorder during their lifetime.
- Brain diseases are the leading cause of disability and the second cause of death worldwide.
- **Current available data cohorts remain fragmented and rarely multimodal.**

Objectives

- Build large-scale cohort of patients with brain disorders or at risk of developing them integrating multimodal data.
- Develop multimodal and multiscale foundation models for brain diseases.
- **Accelerate biomarker and drug discovery powered by AI and data science to be a game changer for brain medicine.**

NEURODEGENERATIVE DISEASES

MENTAL HEALTH

RARE DISEASES

DIAGNOSIS

TREATMENT

PREDICTION

PREVENTION

DISEASE MANAGEMENT



Our approach to solve the problem

OneBrain : Redefine boundaries of brain diseases and accelerate therapeutic breakthroughs through large precision brain health cohorts.

- Novel, **patient-centered research-based initiative** at unprecedented scale, grounded on the creation of a **large real-world, trial-ready cohort** with associated **multimodal bioresource** covering the full spectrum of **brain disorders**.
- This will serve as the basis for ambitious research programs **redefining brain disease endotypes based on underlying biological mechanism**, deriving validated **biomarkers**, and developing efficient mechanism-based **targets and drugs**.
- Unprecedented resources for novel **deep learning AI** and **foundation models** dedicated to **brain diseases**.
- Accelerate the transfer of research outcomes **into clinical practice** and real-world applications that directly improve **patient care**.




Prospective real-life precision neuroscience cohort

Only an idea at this stage!

Prospective biobanking of consecutive (in)patients with brain disease from Pitié-Salpêtrière Hospital

> 100,000 patients over 5 years

- Large numbers
- Richness of phenotyping and link with rare disease ntw.
- Ability to standardize clinical imaging on a single site
- Linkage with EHR and clinical imaging (CDW)
- Linkage with drug reimbursement claims
- Population diversity (underrepresented North-Africans)
- Enabling precision medicine for brain diseases



MOUNT SINAI AIMS TO SCALE ONE-MILLION-GENOME PEAK

Fit for **HORIZON-HLTH-2027-02-TOOL-01-two-stage**: **Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic non-communicable diseases**

- Addressing a major health challenge of the 21st century, aligned with the **European Health Data Space program**.
- **Cross-sectoral and innovation driven by nature**: clinical research, pharmaceuticals, medtech, digital health, diagnostics and data science.
- **Public–private collaboration is essential** to translate multimodal data into clinical and societal impact, transformative for neurology and psychiatry
 - Industry contributions: imaging devices, digital monitoring, AI pipelines, biomarkers, data analytics.
 - Academic & hospital contributions: patient recruitment, clinical data, biological samples, regulatory and ethical oversight
- This collaboration will generate **immediate economic benefits and enhance Europe’s long-term competitiveness** in this strategic field of healthcare.



Outcomes and Impact

- A first-of-its-kind, large longitudinal, recallable and interoperable cohort and associated bioresource dedicated to brain diseases leveraging genetics, multiomics, neuroimaging and neurophysiological profiling.
- Acceleration of biomarker and drug discovery powered by integrated AI and data science
- A platform for swift implementation of innovative clinical trial designs, and pioneering novel precision brain health strategies
- Advances in ethics and sustainability in precision brain health research and care

Impacts:

- Earlier diagnosis and improved patient stratification.
- Enhanced treatment development and reduced burden of brain disorders.
- Strengthened competitiveness of the EU health industry and leadership in brain innovation



Expertise and resources

We have:

- Leading public-private research institute affiliated with Sorbonne University, AP-HP, Inserm, and CNRS. Home to 29 multidisciplinary research teams spanning fields from genomics and molecular biology to systems neuroscience, neuroimaging, and behavior.
- AI and data science center
- Capabilities to implement large cohorts and international partnerships. Our organizational model brings together patients, clinicians, researchers, and industry partners


● We are looking for:

- Reinforcement in AI models for biomarker and therapeutic target identification
- Technologies for multiomics, advanced genetics, brain imaging...
- Healthtech companies to develop fluid, imaging and digital biomarkers



OneBrain Data Workflow: Strategic Partnership Framework

Comprehensive Partnership Ecosystem



Strategic Partner Roles

Cloud & Infrastructure

Provide platforms, analysis tools, and software services enabling scalable **data processing and secure storage solutions**.

Pharmaceutical & Biotech


Fund high-throughput **genomics, multi-omics, and imaging assays** in exchange for time-limited exclusivity and early data access for drug discovery.

AI Technology Firms

Deploy machine learning models (dev. of AI foundation model) for data exploration, patient stratification, and predictive analytics, accelerating precision health advances.




Paris Brain Institute Center for AI and Data Science




Interdisciplinary continuum


**World-class
Neuroscience
expertise**




AI & data science catalyzer



**Dynamic
innovation
ecosystem**



Neuroscience for AI and AI for Neuroscience




AI to tackle the challenge of multimodal and multiscale integration


Multimodal data



Electronic Health Records



Images




Temporal signals



Multi-omics

Multiscale integration



Paris Brain Institute Innovation



Innovation at Paris Brain Institute

Creating a virtuous cycle

Philanthropic fund NeurAL

Exit = return on investment

Pre-maturation



VC fundraising



Acceleration



Startup Studio

Applied research



Sleeping Beauties

Fundamental research



Some landmark papers

- **Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.** Dubois et al., [Lancet Neurol. 2018](#)
- **Mapping the fine scale organization and plasticity of the brain vasculature.** C. Kirst. et al. [Cell 2020](#)
- **A neurodevelopmental origin of behavioral individuality in the Drosophila visual system.** Linneweber GA et al. [Science 2020](#)
- **Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival.** A. Chiot et al. [Nature Neuroscience 2020](#)
- **The Geometry of Abstraction in the Hippocampus and Prefrontal Cortex.** Munuera J. [Cell 2020](#)
- **Neural mechanisms resolving exploitation-exploration dilemmas in the medial prefrontal cortex.** Domenech P. et al. [Science 2020](#)
- **Four core properties of the human brain valuation system demonstrated in intracranial signals.** Lopez-Persem A, et al. [Nature Neurosciences 2020](#)
- **Mechanisms and therapeutic implications of hypermutation in gliomas,** M. Touat et al. [Nature 2020](#)
- **Huntington's disease alters human neurodevelopment.** Barnat et al. [Science 2020](#)
- **Treating early postnatal circuit defect delays Huntington's disease onset and pathology in mice.** Barnat et al. [Science 2022](#)
- **Somatic PIK3CA Mutations in Sporadic Cerebral Cavernous Malformations.** Peyre et al. [New England Journal of Medicine 2021](#)
- **Edinger-Westphal peptidergic neurons enable maternal preparatory nesting** Topilko T et al. [Neuron 2022](#)
- **GluN3A excitatory glycine receptors control adult cortical and amygdalar circuits.** Bossi et al. [Neuron 2022](#)
- **Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL): a multicentre, randomised, double-blind, placebo-controlled trial,** G. Coarelli & al., [The Lancet Neurology 2022](#)
- **The mesencephalic locomotor region recruits V2a reticulospinal neurons to drive forward locomotion.** Carbo-Tano M. et al. [Nature Neuroscience 2023](#)
- **Long-range inhibition synchronizes and updates prefrontal task activity.** Cho et al. [Nature 2023](#)
- **Multimodal assessment improves neuroprognosis performance in clinically unresponsive critical care patients with brain injury.** Rohaut et al. [Nature Medicine 2024](#)
- **Targeting pathological cells with senolytic drugs reduces seizures in neurodevelopmental mTOR-related epilepsy.** Ribierre et al. [Nature Neuroscience 2024](#)





Thank You





Happy Homework: scaling
movement-supportive
homework practices in
European schools

- **Dr Samantha Robinson**
- The University of the West of Scotland
- Scotland, United Kingdom
- **Topic of interest:** HORIZON-HLTH-2026-01-STAYHLTH-02 - Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people




Happy Homework

- School-based homework intervention aiming to limit demands on schools
- Homework tasks promoting 24-hour movement behaviours
- Theoretically underpinned
- Mapped to Scottish Curriculum
- Inclusive, requiring no access to equipment or costly facilities
- Shown to significantly improve:
 - (a) Physical activity (stepping time)
 - (b) Sleep duration
 - (c) Fruit and vegetable consumption¹

¹ Donnelly, S., Buchan, D. S., McLellan, G., Roberts, R., & Arthur, R. (2023). Exploring the feasibility of a cluster pilot randomised control trial to improve children's 24-hour movement behaviours and dietary intake: Happy homework. *Journal of Sports Sciences*, 41(19), 1787-1800.



- Co-create country- and curricula-specific versions of Happy Homework through participatory approaches with teachers, parents and children
- Measure the effectiveness of Happy Homework in:
 - (a) Improving children's sleep
 - (b) Increasing children's physical activity
 - (c) Reducing children's sedentary behaviour
- Explore experiences of teachers, parents and children regarding Happy Homework across Europe



Our expertise


- Behavioural Science and Public Health: designing and implementing behaviour change interventions for health outcomes
- Epidemiology and Non-Communicable Diseases: defining and measuring indicators of intervention success and health outcomes
- Data Science: use of digital tools including wearables and app-based design and development in-house
- Healthcare and Education implementation: integrating interventions into schools and assessing health promotion in these environments



Partnerships

- Established partnerships across the UK and Ireland
- Expanded partnerships with countries including America, Spain and Finland
- Additional collaborators with expertise in:
 - (a) Access to local authorities and educational institutions
 - (b) Strong qualitative skills in conducting interviews with children
 - (c) Expertise in wearable technology and accelerometry research
 - (d) Proficiency in app development

Keep in touch with us:



samantha.Robinson@uws.ac.uk



[Samantha Robinson - The UWS
Academic Portal](#)



[@DrSamRobinson](#)

Thank you



Collaborative Suicide Prevention

Dr M. May Seitanidi

University of Kent, Kent Business School

UK

mmayseitanidi@yahoo.com & m.m.seitanidi@kent.ac.uk

<https://research.kent.ac.uk/gcdc/person/m-may-seitanidi/>

- **HORIZON-HLTH-2026-01-DISEASE-03:** Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
- **HORIZON-HLTH-2026-01-DISEASE-09:** Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
- **HORIZON-HLTH-2026-01-CARE-03:** Identifying and addressing low-value care in health and care systems Call: Cluster 1 - Health (Single stage - 2026)

Collaborative Suicide Prevention 1

- Complex social problems have proven hard to tackle including climate change, public health problems (Jones et al., 2016) and suicide, a major global public health issue affecting annually **directly 21 million and indirectly 108 million people**; hence the suicide reduction rate is now included in the UN SDGs (Target 3.4, reduction by 1/3 by 2030)
- UK Government Multi-agency approach (DoH, 2012; 2017) and local SP plans (Public Health England, 2016) calling for broad commitment **across government, voluntary organisations, the industry and academia to collaborate** for place-based prevention for improved implementation measures.

GAP:

Absence of studies examining the development of **early stage collaborative solutions focusing on prevention and on the social issue**

WHY IMPORTANT:

development of **norms, setting expectations and courses of action** across policy communities (multi-sectoral approaches and multi-disciplinary teams) in Suicide Prevention (SP), critical for the uptake and effectiveness of Collaborative SP (C-SP)

Collaborative Suicide Prevention 2

OBJECTIVES:

1/ Map how local authorities currently **coordinate suicide prevention efforts** across sectors beyond healthcare: Identify strengths, gaps, and patterns in implementation.

2/ Analyse key enablers and barriers to **effective multisector collaboration** in suicide prevention: focus on governance, policy alignment, trust-building, and resourcing.

3/ Co-develop and pilot a collaborative implementation framework with selected local authorities: Integrate public, voluntary, and occupational sectors in real-world settings.

4/ Evaluate the impact of this framework on coordination, uptake, and preventative outcomes: Use mixed methods to assess effectiveness, feasibility, and transferability.

5/ Produce actionable recommendations for scaling collaborative suicide prevention across EU contexts

MY EXPERTISE: CSSP for Social Problems: Social inclusion, Biodiversity; Emergency Medical Service Provision; Suicide Prevention in Higher Education in England; Suicide Prevention in construction

Existing Partner Organisations: University of Kent, Healthy Empowered Communities Royal Docks Centre for Sustainability (UEL),

Previous Participation:

Canadian Funded Research Projects; Funded PhD projects; University-funded research projects

Building Public Trust in Life Sciences through Science Trust Labs

Lesia Perederko, PhD

ANDès (Association Nationale des Docteurs, France)
Administrative Board Member

Affiliated networks: ICoRSA | COST Action

France / Ukraine

Lesiaperederko1907@gmail.com

www.linkedin.com/in/lesia-perederko-6598b832b

Expertise & Key Contribution Parameters

Parameter	Content
Goal	to strengthen public trust in the life sciences through <i>innovative communication models</i> , community engagement, and educational tools.
Focus / Key Priorities	<i>transforming complex scientific concepts</i> through the development of a European Science Trust Platform that connects researchers, educational institutions, civil society organisations, and media actors
Format of Work	the <i>development of interactive educational modules</i> , publication of science-based articles in mainstream and specialised media, and the implementation of <i>effective public engagement activities</i> . A specific focus is placed on working with young people as ambassadors of science advocacy, including through summer schools and capacity-building initiatives.
Expected Outcomes	include <i>increased citizen integration</i> into scientific processes, strengthened integrity in public discourse, and reduced health-related misinformation. The project will also establish <i>clear, transparent communication channels</i> between the scientific community and society.

Expertise & organisational embeddedness

- ***Academic background*** in molecular biology and human genetics, with experience in biomedical research and life sciences education. Translating complex scientific topics to the audience.
- ***Analytical documentation*** expertise and policy-oriented reports addressing international researcher mobility and science advocacy.
- Project ***concept initiator*** on building collaborative hubs at the European level.

Existing partnerships & potential needs for additional partners

Active collaboration within European researcher **advocacy and policy networks** (ANDès, ICoRSA, Eurodoc), communication with partners of **UK-Ukraine Academic mentoring program, scientific diaspora.**

Potential needs for additional partners

- Research-performing organizations and universities willing to pilot Science Trust Labs at local and national levels.
- Science communication and media partners with expertise in public outreach, journalism, and digital engagement.
- Civil society organizations and patient associations to support co-creation and community engagement.

I am fully open to collaboration and committed to constructive and effective dialogue within multidisciplinary and international consortia



Cluster 1 Health



From bench to bedside in autoimmune diseases with a focus on systemic lupus eruthematosus

Yves Renaudineau, PharmD, PhD

Laboratory of Immunology, CHU Toulouse (head)

Toulouse University Medical School, Infinity, INSERM, CNRS

France

Renaudineau.y@chu-toulouse.fr

[Yves RENAUDINEAU](#) - [Google Scholar](#)



- **Areas/Topic of Interest:**

- Autoimmune diseases, with a focus on SLE.
- SLE affects 0.5-1 per 1,000 individuals.
- Predominantly females and 20% of pediatric cases.
- Suboptimal therapeutic response: only 50% of patients achieve complete remission within 1-2 years.
- Inadequate disease control: 40% of patients experiencing disease flares within a 2-year period.

- **Objectives of the Proposal:**

- To identify and analyze the underlying factors contributing to poor therapeutic response and disease flares, encompassing fundamental research, translational studies, and aspects related to therapy selection and management.
- To evaluate critical variables and determine those with the highest discriminatory power.
- To develop and evaluate practical and actionable recommendations based on these findings.

- **Expertise, Organizational Structure, and Collaborations, and needs**



- **Core Focus: Type I/II Interferon Pathway**

- **Specialization in immunogenetics including genetic analysis encompassing Chromosome X abnormalities, rare variants, human T and B lymphocytes, and implementation of functional testing.**
- **Location: Sex and Immunity Research Team, Infinity INSERM-CNRS, Toulouse, France**
- **Collaborative Partnerships:**
 - United Kingdom jSLE cohort at the University of Liverpool (Professor C. Hedrich)
 - Computational variant modeling at the University of Tampa (Dr. C. Brooks)
- **Need 1: Genetics expertise focusing on mosaicism during disease progression**
- **Need 2: Development of high-throughput methodologies for assessing missense mutations and functional genetic variants**



- **Expertise, Organizational Structure, and Collaborations, and needs**
- **Translational Research: Autoantibodies, complement system, cellular immunology, cytokine profiling, and urinary biomarkers**
- **Technical Expertise: In charge of an immunological platform adhering to ISO 15189 standards with over 50 routine laboratory biomarkers for SLE.**
- **Location: CHU Toulouse Medical Reference Laboratory (LBMR) specializing in lupus and scleroderma**
- **Collaboration: European Autoimmunity Standardisation Initiative (EASI)**
- **Need 1: Creation of computational tools integrating clinical data with genetic, cellular, and immunological parameters**
- **Need 2: Access to validation cohorts for biomarker assessment**
- **Clinical Resources:**
 - **Active patient registry including over 400 SLE cases, more than 200 systemic sclerosis (SSc) patients, as well as individuals with myositis and long COVID.**
 - **Biological samples are collected at diagnosis and throughout follow-up periods.**
 - **Institutional support provided by the clinico-biological biobank at CHU Toulouse.**



- **Previous projects**

- **IMI PRECISESADS project: Responsible for autoantibody and complement biomarker analyses involving a cohort of 2,500 patients; serving as co-investigator.**
- **STIMULES project: Development of monoclonal antibodies in MRL/Lpr lupus-prone mice. Principal investigator**
- **Rheumatoid arthritis, risk factors and super-enhancers project. Russian Science Foundation (RSF). Principal investigator**
- **Epigenetics in Sjögren's syndrome, and lymphocytic leukemia. AFGS and Laurette Fuguain foundations. Principal investigator**

Contact: renaudineau.y@chu-toulouse.fr